Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
LXEO Lexeo Therapeutics	$3.91 -7.8%	$3.36	$1.45 ▼ $19.50	$140.76M	0.52	530,698 shs	756,031 shs
MRVI Maravai LifeSciences	$2.06 +2.5%	$2.09	$1.67 ▼ $10.03	$511.87M	0.25	2.33 million shs	2.18 million shs
RLAY Relay Therapeutics	$3.19 -5.1%	$3.06	$1.78 ▼ $10.72	$576.05M	1.59	2.09 million shs	2.37 million shs
VECT VectivBio	$16.85	$16.85	$4.25 ▼ $16.98	N/A	N/A	N/A	N/A

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
LXEO Lexeo Therapeutics	-7.78%	-0.76%	+27.78%	+44.28%	-75.00%
MRVI Maravai LifeSciences	+2.49%	-3.29%	-8.44%	-9.25%	-70.10%
RLAY Relay Therapeutics	-5.06%	-0.93%	+11.54%	+4.25%	-54.62%
VECT VectivBio	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
LXEO Lexeo Therapeutics	3.1818 of 5 stars	4.5	2.0	0.0	0.0	1.4	2.5	0.6
MRVI Maravai LifeSciences	3.9248 of 5 stars	3.1	3.0	0.0	4.4	1.4	0.8	1.3
RLAY Relay Therapeutics	2.2386 of 5 stars	3.4	2.0	0.0	0.0	1.3	2.5	0.6
VECT VectivBio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
LXEO Lexeo Therapeutics	3.00	Buy	$16.60	324.55% Upside
MRVI Maravai LifeSciences	2.25	Hold	$6.64	222.28% Upside
RLAY Relay Therapeutics	2.83	Moderate Buy	$17.67	453.81% Upside
VECT VectivBio	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest LXEO, MRVI, RLAY, and VECT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/30/2025	LXEO Lexeo Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$16.00 ➝ $10.00
5/16/2025	LXEO Lexeo Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$23.00 ➝ $15.00
5/13/2025	LXEO Lexeo Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$22.00 ➝ $20.00
5/13/2025	MRVI Maravai LifeSciences	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $10.00
5/13/2025	MRVI Maravai LifeSciences	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$3.00 ➝ $2.00
5/7/2025	RLAY Relay Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $10.00
4/17/2025	RLAY Relay Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Equal Weight	$4.00
4/8/2025	LXEO Lexeo Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$25.00 ➝ $22.00
4/8/2025	LXEO Lexeo Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00 ➝ $23.00
3/26/2025	LXEO Lexeo Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00 ➝ $23.00
3/25/2025	LXEO Lexeo Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$24.00 ➝ $20.00

(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
LXEO Lexeo Therapeutics	$650K	199.71	N/A	N/A	$3.53 per share	1.11
MRVI Maravai LifeSciences	$259.18M	2.02	$0.63 per share	3.25	$2.28 per share	0.90
RLAY Relay Therapeutics	$10.01M	54.64	N/A	N/A	$4.65 per share	0.69
VECT VectivBio	$27.34M	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
LXEO Lexeo Therapeutics	-$98.33M	-$3.30	N/A	N/A	N/A	N/A	-85.86%	-68.48%	8/11/2025 (Estimated)
MRVI Maravai LifeSciences	-$144.85M	-$1.14	N/A	N/A	N/A	-67.14%	-12.91%	-6.87%	8/6/2025 (Estimated)
RLAY Relay Therapeutics	-$337.71M	-$2.23	N/A	N/A	N/A	N/A	-44.17%	-39.53%	8/5/2025 (Estimated)
VECT VectivBio	-$93.74M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest LXEO, MRVI, RLAY, and VECT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	LXEO Lexeo Therapeutics	-$0.80	-$0.99	-$0.19	-$0.99	N/A	N/A
5/12/2025	Q1 2025	MRVI Maravai LifeSciences	-$0.07	-$0.08	-$0.01	-$0.21	$44.01 million	$46.85 million
5/5/2025	Q1 2025	RLAY Relay Therapeutics	-$0.50	-$0.46	+$0.04	-$0.46	$0.01 million	$7.68 million
3/24/2025	Q4 2024	LXEO Lexeo Therapeutics	-$0.87	-$0.78	+$0.09	-$0.78	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
LXEO Lexeo Therapeutics	N/A	N/A	N/A	N/A	N/A
MRVI Maravai LifeSciences	N/A	N/A	N/A	N/A	N/A
RLAY Relay Therapeutics	N/A	N/A	N/A	N/A	N/A
VECT VectivBio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
LXEO Lexeo Therapeutics	0.01	3.42	3.42
MRVI Maravai LifeSciences	0.60	5.96	5.17
RLAY Relay Therapeutics	N/A	19.96	19.96
VECT VectivBio	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
LXEO Lexeo Therapeutics	60.67%
MRVI Maravai LifeSciences	50.25%
RLAY Relay Therapeutics	96.98%
VECT VectivBio	N/A

Insider Ownership

Company	Insider Ownership
LXEO Lexeo Therapeutics	5.30%
MRVI Maravai LifeSciences	2.11%
RLAY Relay Therapeutics	4.87%
VECT VectivBio	9.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
LXEO Lexeo Therapeutics	58	33.20 million	31.44 million	Not Optionable
MRVI Maravai LifeSciences	610	254.66 million	249.29 million	Optionable
RLAY Relay Therapeutics	330	171.45 million	163.10 million	Optionable
VECT VectivBio	30	N/A	N/A	No Data

LXEO, MRVI, RLAY, and VECT Headlines

Recent News About These Companies

Ironwood’s shares sink as FDA demands new trial for lead drug

April 15, 2025 | msn.com

A brain biotech launches with Roche’s spare parts

February 13, 2025 | biopharmadive.com

Aravax Continues International Expansion with Appointment of Aled Williams as Chief Business Officer

January 21, 2025 | markets.businessinsider.com

CDR-Life Appoints Sarah Holland, PhD, as Chief Business Officer

December 5, 2024 | finance.yahoo.com

Recent advances in clinical practice: mastering the challenge—managing IBS symptoms in IBD

November 12, 2024 | gut.bmj.com

Graft versus Host Disease Market to Increase at a CAGR of 9.9% During the Study Period (2020–2034) | DelveInsight

September 23, 2024 | finance.yahoo.com

Etherio Group: 2024 CMI 25

September 21, 2024 | meetingsnet.com

Compare with VectivBio Holding AG (VECT)

May 29, 2024 | msn.com

enGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of Directors

May 15, 2024 | finance.yahoo.com

Vicore Pharma Holding: Vicore Expands and Strengthens its Board of Directors

May 14, 2024 | finanznachrichten.de

Vicore Expands and Strengthens its Board of Directors

May 14, 2024 | finance.yahoo.com

Short Bowel Syndrome Market by 2032: Forecast Report Estimates Significant Growth

April 5, 2024 | uk.finance.yahoo.com

FDA approves DMD treatment from Italfarmaco

March 31, 2024 | cen.acs.org

Pipeline moves: Approval prospects for SBS candidate rise after Phase III trial meets endpoints

March 18, 2024 | msn.com

Ironwood Nabs Phase III Win, Still Sees Stock Nosedive

March 1, 2024 | biospace.com

Ironwood felled by mixed data in short bowel syndrome trial

March 1, 2024 | pharmaphorum.com

UPDATE 3-Ironwood's bowel disease drug meets main goal of late-stage study

March 1, 2024 | msn.com

Ironwood's bowel disease treatment meets main goal in late-stage trial

February 29, 2024 | reuters.com

Why Is Gastrointestinal Healthcare Focused Ironwood Pharmaceuticals Stock Sinking On Thursday?

February 29, 2024 | benzinga.com

Only two sleeps left until February 31!

February 29, 2024 | ft.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LXEO, MRVI, RLAY, and VECT Company Descriptions

Lexeo Therapeutics NASDAQ:LXEO

$3.91 -0.33 (-7.78%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$3.89 -0.02 (-0.51%)

As of 06/20/2025 06:43 PM Eastern

Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.

Maravai LifeSciences NASDAQ:MRVI

$2.06 +0.05 (+2.49%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$2.11 +0.05 (+2.43%)

As of 06/20/2025 07:50 PM Eastern

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.

Relay Therapeutics NASDAQ:RLAY

$3.19 -0.17 (-5.06%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$3.18 -0.01 (-0.31%)

As of 06/20/2025 04:20 PM Eastern

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

VectivBio NASDAQ:VECT

$16.85 0.00 (0.00%)

As of 06/18/2025

VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, which is in Phase II clinical trial for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD). VectivBio Holding AG was incorporated in 2019 and is headquartered in Basel, Switzerland. As of June 29, 2023, VectivBio Holding AG operates as a subsidiary of Ironwood Pharmaceuticals, Inc.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time